

Key Trastuzumab Biosimilars Market Trend 2024-2033: Focus on New Product Launches

The Business Research Company's Trastuzumab Biosimilars Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UNITED KINGDOM, October 24, 2024 /EINPresswire.com/ -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports—limited time only!



The <u>trastuzumab biosimilars market</u> is experiencing exponential growth, projected to rise from \$4.27 billion in 2023 to \$5.43 billion in 2024, with an impressive CAGR of 27.1%. Contributing



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs"
The Business Research
Company

factors include market expansion, patent expirations, rapid biosimilar development, and competitive pricing strategies.

What Are the Market Size Estimates for the Global Trastuzumab Biosimilars Market and Its Expected Growth Rate?

The market is expected to see exponential growth, projected to reach \$14.69 billion by 2028 at a CAGR of 28.3%. This growth is fueled by intensified market competition, advancements in the biosimilar pipeline, and increasing physician adoption. Major trends include improved access to biosimilars, targeted market segmentation strategies, and educational campaigns to boost acceptance.

Access a Comprehensive Sample Report for Exclusive Insights Into the Global Trastuzumab Biosimilars Market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

What Are The Primary Growth Drivers Of The Trastuzumab Biosimilars Market?

The rising incidence of breast and gastric cancer is expected to boost the market. Trastuzumab biosimilars are crucial in treating human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the American Cancer Society, approximately 297,790 new cases of invasive breast cancer are expected to be diagnosed in women in 2023, leading to a substantial demand for cost-effective trastuzumab biosimilars, thus driving market growth.

Pre-book the report for a swift delivery:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Who Are The Top Market Players Contributing To The Growth Of The Trastuzumab Biosimilars Market?

Major companies operating in the market report are Pfizer Inc., Outlook Therapeutics Inc., Merck & Co., Amgen Inc., BioXpress Therapeutics SA, Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co.Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsungbioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Sunshine Guojian Pharmaceutical Co. Ltd., Shanghai CP Guojian Pharmaceutical Co.Ltd., Alvotech Holdings S.A, Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., PlantForm Corporation, STC Biologics Ltd., Prestige BioPharma Limited, Protheragen Inc., AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited, Reliance Life Sciences Pvt. Ltd.

What Emerging Trends Are Affecting The Size Of The Trastuzumab Biosimilars Market?

Major companies operating in the market are increasing their efforts to introduce new products and get them approved by government bodies to gain a competitive edge in the market. A drug launch refers to the introduction of a new pharmaceutical product, typically a medication, into the market for commercial use and distribution. The drug approval process involves multiple stages, including preclinical testing and clinical trials to review the drug's effects.

How Is the Global Trastuzumab Biosimilars Market Segmented?

The trastuzumab biosimilars market covered in this report is segmented -

- 1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
- 2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
- 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Geographical Analysis: North America Emerges as the Trastuzumab Biosimilars Market Leader

North America was the largest region in the market in 2023. Middle East is expected to be the fastest growing region in the market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Trastuzumab Biosimilars Market Definition and Overview

Trastuzumab biosimilars are innovative HER2-targeted therapies designed for the treatment of early and metastatic HER2-positive breast cancers. As monoclonal antibodies, they effectively bind to the HER2/neu receptor, rendering it inactive and significantly improving patient outcomes.

The <u>Trastuzumab Biosimilars Global Market Report 2024</u> from The Business Research Company includes the following key information:

- Market size data for both historical and future periods
- Analysis of both macro and microeconomic factors that have impacted the market over the past five years
- Regional market analysis covering Asia-Pacific, China, Western Europe, Eastern Europe, North America, the USA, South America, and the Middle East and Africa
- Country-specific market analysis for Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

Overview of the Global Trastuzumab Biosimilars Market Report: Trends, Opportunities, Strategies, and More

The Trastuzumab Biosimilars Global Market Report 2024 from The Business Research Company is an extensive resource that delivers insights into <u>trastuzumab biosimilars market size</u>, trastuzumab biosimilars market drivers and trends, trastuzumab biosimilars market major players, trastuzumab biosimilars competitors' revenues, trastuzumab biosimilars market positioning, and growth across geographies. This report provides valuable in-depth insights into potential opportunities and strategies. Companies can utilize the information presented to target segments with the greatest growth potential.

Browse Through More Similar Reports By The Business Research Company: Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Oncology Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

What Services Does The Business Research Company Offer?

The Business Research Company has published more than 15,000 reports spanning 27 industries and over 60 regions. Our research is supported by 1.5 million datasets, thorough secondary research, and unique insights gained from interviews with industry experts. We offer ongoing and customized research services, featuring a variety of specialized packages designed to meet your specific needs, such as Market Entry Research, Competitor Tracking, Supplier & Distributor Packages, and many others.

Our flagship product, the Global Market Model, serves as a leading market intelligence platform that provides comprehensive and updated forecasts to facilitate informed decision-making.

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/754454908

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.